There is ongoing research evaluating the role of PD‐L1 expression, tumor mutational burden (TMB), molecular subtyping and DNA damage response (DDR) gene alterations, among other biomarkers, as potential predictors of response to anti‐PD‐1/PD‐L1 agents, but no consensus or clinical utility that impacts clinical decision making has yet been reached for the vast majority.3, 4. This evidence concerns the gene CD274 and neoplasm.